Nrx pharmaceuticals announces second favorable safety report for zyesami™ (aviptadil) in nih sponsored activ-3b critical care study in patients with life-threatening covid-19

Radnor, pa., sept. 29, 2021 /prnewswire/ -- nrx pharmaceuticals (nrx) (nasdaq: nrxp), a clinical stage, biopharmaceutical company today provided a safety update on zyesami™ (aviptadil) which is being tested in the activ-3b critical care phase 3 study sponsored by the national institutes of health.
NRXP Ratings Summary
NRXP Quant Ranking